Liraglutide improves weight loss in people who are overweight or obese, study showsBMJ 2015; 351 doi: http://dx.doi.org/10.1136/bmj.h3545 (Published 02 July 2015) Cite this as: BMJ 2015;351:h3545
- Susan Mayor
Liraglutide significantly reduces body weight and improves metabolic control in people who are obese or overweight and have dyslipidaemia or hypertension, a randomised trial reported in the New England Journal of Medicine has shown.1
The study randomised 3731 people who were obese, had a body mass index (BMI) of at least 30, or were overweight (BMI>27), and who had treated or untreated dyslipidaemia or hypertension, to treatment with once daily injections of liraglutide (3.0 mg) or placebo in addition to counselling on lifestyle changes.
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial